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Abstract
Pre-symptomatic screening of genetic alterations might help identify subpopulations of individuals that could enter
into early access prevention programs. Since liquid biopsy is minimally invasive it can be used for longitudinal studies
in healthy volunteers to monitor events of progression from normal tissue to pre-cancerous and cancerous condition.
Yet, cell-free DNA (cfDNA) analysis in healthy individuals comes with substantial challenges such as the lack of large
cohort studies addressing the impact of mutations in healthy individuals or the low abundance of cfDNA in plasma. In
this study, we aimed to investigate the technical feasibility of cfDNA analysis in a collection of 114 clinically healthy
individuals. We ﬁrst addressed the impact of pre-analytical factors such as cfDNA yield and quality on sequencing
performance and compared healthy to cancer donor samples. We then conﬁrmed the validity of our testing strategy
by evaluating the mutational status concordance in matched tissue and plasma specimens collected from cancer
patients. Finally, we screened our group of healthy donors for genetic alterations, comparing individuals who did not
develop any tumor to patients who developed either a benign neoplasm or cancer during 1–10 years of follow-up
time. To conclude, we have established a rapid and reliable liquid biopsy workﬂow that allowed us to study genomic
alterations with a limit of detection as low as 0.08% of variant allelic frequency in healthy individuals. We detected
pathogenic cancer mutations in four healthy donors that later developed a benign neoplasm or invasive breast cancer
up to 10 years after blood collection. Even though larger prospective studies are needed to address the speciﬁcity and
sensitivity of liquid biopsy as a clinical tool for early cancer detection, systematic screening of healthy individuals will
help understanding early events of tumor formation.
Introduction
Genomic instability arises in normal cells through
accumulation of genetic and epigenetic changes and has
been shown to occur over a variable time span, ranging
from years to decades1–4. The vast majority of normal
cells that have acquired mutations is cleared away by the
immune system, while a minimal fraction might even-
tually progress and give rise to cancer5. Upon develop-
ment of cancer, speciﬁc genomic alterations can be
identiﬁed and used to provide the rationale for speciﬁc
treatment options. Monitoring genomic changes could
hence be crucial to identify early mutational events that
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are associated with higher risk of developing cancer, but it
is largely unfeasible using traditional tissue-based
approaches due to the lack of observable tumor lesions.
In contrast, liquid biopsy might offer the possibility of
detecting early genomic aberrations and investigating
cancer evolution in a minimally invasive fashion. Liquid
biopsy is a broad term that refers to testing body ﬂuids
such as blood or urine for biomarkers reconcilable with a
medical condition. In the ﬁeld of oncology, liquid biopsy
mainly pertains to the analysis of circulating tumor DNA
(ctDNA) in blood. Circulating tumor DNA represents
only a minor fraction (<0.1–10%) of the total circulating
cell-free DNA (cfDNA)6, which is derived by cell death
associated to physiological tissue remodeling events7. The
majority of DNA fragments found in the circulation
measures ~180 nucleotides in size8, suggesting that
apoptosis and necrosis are responsible for cfDNA shed-
ding. Interestingly, the blood of cancer patients typically
presents higher levels of circulating cfDNA compared to
healthy individuals9,10.
A growing body of evidence supports ctDNA-based
analysis of cancer-associated hotspot mutations as a cost-
effective and highly sensitive tool, complementary to tis-
sue molecular proﬁling11–15. In clinical settings, ctDNA
analysis has been applied to monitor response to treat-
ment, to detect residual disease and to identify mechan-
isms of resistance to therapy16–18. Currently, the most
common clinical use of liquid biopsy is the detection of
resistance-associated mutations to inform treatment
decision19–22. The introduction of molecular barcodes has
considerably enhanced the sensitivity of sequencing
methods at the price of additional costs linked to the high
depth of sequencing required (i.e. ~25,000 cover-
age)13,23,24. Taking advantage of this and further techno-
logical developments, several studies have described
clinically relevant genetic alterations in patients with
early-stage cancers at a sensitivity below one mutant
template molecules per milliliter of plasma9,25–28. Never-
theless, among the potential clinical applications of
ctDNA analysis, early detection remains the most ambi-
tious. Several challenges need to be addressed and large
validation studies will be required to establish the sensi-
tivity and speciﬁcity for such testing approach29. The
presence of somatic mutations in asymptomatic patients,
related to clonal hematopoiesis28 as well as clonal
expansion in healthy tissue30–33, could potentially lead to
false-positive calls. Moreover, the recovery and char-
acterization of cfDNA in healthy individuals might prove
challenging, given that cfDNA is less abundant in these
subjects34,35 and only a few studies have reported the
analysis of cfDNA in healthy controls28,36.
An adequate technical validation is therefore required
to allow the implementation of liquid biopsy as a tool for
early cancer detection and prove that extraction and
analysis of cfDNA isolated from healthy individuals is
technically achievable. To this end in our proof of prin-
ciple study, we examined the feasibility cfDNA inter-
rogation in a collection of 114 individuals that were
clinically healthy (i.e. not affected by any manifest medical
condition) at the time of blood draw.
First, we analyzed the impact of pre-analytical factors
such as cfDNA yield and quality on sequencing perfor-
mance parameters as molecular coverage and limit of
detection, comparing samples from healthy and cancer
donors.
We then evaluated the reliability of our testing strategy
by analyzing cfDNA samples obtained from patients with
a histologically conﬁrmed diagnosis of breast or lung
cancer. Speciﬁcally, we assessed the concordance of spe-
ciﬁc genetic alterations detected in matched tissue and
plasma specimens. Finally, we investigated the mutational
status of a group of healthy donors comprising both
individuals that did not develop any tumor within 1 to 10
years (average= 8.5 years; Table 1) of follow-up as well as
individuals that developed either a benign neoplasm or
cancer during the follow-up time. Altogether, our study
demonstrates the technical feasibility of extracting and
analyzing cfDNA in healthy individuals to study genomic
alterations, by means of molecular barcoded next-
generation sequencing (NGS).
Materials and methods
Patients
One hundred and fourteen healthy donors undergoing a
control screening mammography test and nine breast
cancer patients undergoing treatment at the Breast Can-
cer Unit and Translational Research Unit of the Hospital
of Cremona (Italy) were selected for this study (Ethical
approval protocol nr. Ex01/4111/04). In addition, 54 lung
cancer patients undergoing treatment at the University
Hospital Basel (Switzerland) were selected for this study
(Ethical approval protocol EKBB/EKNZ 31/12). The study
was performed in compliance with all relevant ethical
regulations. More plasma was available in the cancer
patient group (from 1.5 to 5.5 ml) in cancer patients
because 2 × 10ml of whole blood was collected for each
patient. Conversely, only 1 × 10ml whole blood was
drawn from healthy individuals, part of which was used
for other analyses, resulting in a ﬁnal plasma volume
ranging from 0.4 to 2.0 ml. Follow-up data have been
collected in the frame of this study only for donors that
were clinically healthy at blood collection.
cfDNA/DNA extraction from plasma and tissue samples
Blood samples were collected in either K2EDTA tubes
(BD Vacutainer® Blood Collection Tubes, Becton Dick-
inson, Franklin Lakes, USA) and Cell-Free DNA BCT®
(Streck, La Vista, NE). The plasma fraction was separated
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from the blood cells by two consecutive rounds of cen-
trifugation for 30min at room temperature at 1600 × g.
The collected plasma was aliquoted and stored at −80 °C
until use. cfDNA was extracted from plasma volumes
ranging from 0.4 to 5.5 ml using the MagMax Cell-Free
Total Nucleic Acid Isolation Kit (Thermo Fisher Scien-
tiﬁc, Waltham, USA) according to the manufacturers’
instructions. The cfDNA quantity was assessed with the
dsDNA HS assay kit by the Qubit 2.0 Fluorometer
(Thermo Fisher Scientiﬁc). cfDNA quality was assessed
with the Agilent High Sensitivity D1000 ScreenTape
System (Agilent Technologies, Santa Clara, USA). Only
cfDNA samples with a clear fragment size peak between
140–200 bp (Supplementary Fig. 1) were considered for
analysis.
Tissue biopsies were obtained at the time of ﬁrst diag-
nosis and inspected through examination of hematoxylin
and eosin-stained slides by a thoracic pathologist. For
DNA extraction, 4–5 FFPE tissue sections of 10 µm
thickness were cut and deparafﬁnized using Xylol. DNA
extraction from tissue was performed using the column-
based RecoverAll Extraction Kit (Thermo Fisher Scien-
tiﬁc) according to the manufacturer’s instructions. DNA
quantity was assessed with the dsDNA HS assay kit by the
Qubit 2.0 Fluorometer (Thermo Fisher Scientiﬁc).
NGS library preparation
For plasma samples, NGS libraries were prepared from
2.5 to 105.5 ng of cfDNA following the HeliXmoker,
HeliXgyn, and HeliXafe workﬂows (patented by The
Bioscience Institute), based on the Oncomine™ Lung
cfDNA Assay v1, the Oncomine™ Breast cfDNA Research
Assay v2, and the Oncomine™ Pan-Cancer Cell-Free Assay
(Thermo Fisher Scientiﬁc), respectively. Only six samples
were selected for a broader mutational analysis using the
HeliXafe protocol, based on the cfDNA concentration and
quality, providing that these six samples matched the
required minimum input for a second round of library
preparation. Our general library preparation protocol was
based on a two-cycle multiplex touch-down PCR reaction
with a temperature range from 64 °C to 58 °C, which
allowed to amplify target regions and introduce unique
molecular identiﬁers. The resulting tagged amplicons of
around 100–140 bp length were then cleaned up using
Agencourt AMPure XP (Beckman Coulter, Brea, USA) at
a bead to sample ratio of 1.5× and puriﬁed products were
eluted in 24 μl low TE buffer. A second round of PCR (18
cycles) was performed in a total volume of 50 μl to amplify
the puriﬁed amplicons and introduce Ion Torrent™ Tag-
Sequencing adapters containing sample-speciﬁc barcodes.
The resulting library of target DNA fragments was pur-
iﬁed by performing a two-step cleanup using Agencourt
AMPure XP (Beckman Coulter) at a bead to sample ratio
of 1.15× and 1.0×, respectively. The puriﬁed libraries were
then diluted 1:1000 and quantiﬁed by qPCR using the Ion
Universal Quantitation Kit (Thermo Fisher Scientiﬁc).
The quantiﬁed stock libraries were then diluted to 100 pM
for downstream template preparation.
For NGS library preparation from tissue samples 5–40 ng
of DNA was used, depending on availability of input
material. Libraries were prepared according to protocol
(Oncomine™ Solid Tumor Assay, Oncomine™ Focus Assay,
Oncomine™ Comprehensive v3 Assay were used (Supple-
mentary Table 1)). The resulting libraries were puriﬁed
using Agencourt AMPure XP (Beckman Coulter). Libraries
were quantiﬁed by qPCR using the Ion Universal Quanti-
tation Kit (Thermo Fisher Scientiﬁc), diluted to 50 pM and
batched according to the manufacturer’s instructions.
Table 1 Patient characteristics
Patient characteristics (n= 177) n (%)
Age (years)
Mean (SD) 63 (11)
Sex (n)
Male 19 (11)
Female 157 (89)
Clinical status at blood collection (n)
No tumor (healthy) 114 (64)
Breast cancer 9 (5)
Lung cancer 54 (31)
Clinical status at follow-upa (n)
No tumor (healthy)—Group I 25 (14)
Benign breast condition—Group II 52 (29)
Breast cancer—Group III 15 (8)
Other tumors—Group IV 14 (8)
Missing information (lost to follow-up) 8 (5)
Follow-up* time from blood collection (years)
Mean (range)—All Groups 8.5 (1.1–10.1)
Mean (range)—Group I 8.7 (4.6–10.1)
Mean (range)—Group II 8.4 (1.1–10.0)
Mean (range)—Group III 9.0 (4.3–10.0)
Mean (range)—Group IV 8.4 (4.1–9.6)
Molecular analysis (n)
Plasma—cfDNA extraction 177 (100)
Plasma—NGS analysis 93 (53)
Tissue—NGS analysis 38 (21)
aFollow-up data have been collected in the frame of this study only for donors
that were clinically healthy at blood collection
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Sequencing
NGS libraries were sequenced on an Ion S5™ instrument
(Thermo Fisher Scientiﬁc) using semiconductor sequen-
cing technology. Brieﬂy, sequencing runs were planned on
the Torrent Suite Software™ v5.8, libraries were pooled and
loaded on an Ion 540™ chip using the Ion Chef™ instru-
ment (Thermo Fisher Scientiﬁc). The loaded chip was then
sequenced using 500 ﬂows. Raw data were processed
automatically on the Torrent Server™ and aligned to the
reference hg19 genome. QC was performed manually for
each sample based on the following metrics; number of
reads per sample > 2,500,000 (for Oncomine™ Lung cfDNA
Assay libraries), >4,000,000 (for Oncomine™ Breast cfDNA
Research Assay v2 libraries) >15,000,000 (for Oncomine™
Pan-Cancer Cell-Free Assay libraries), on-target reads
>90%, read uniformity >90%, median molecular coverage
>500×, median read coverage >15,000.
Tissue NGS libraries were sequenced according to the
manufacturer’s instructions.
The sequencing data of the QC passing samples were
then uploaded in BAM format to the Ion Reporter™
Analysis Server for variant calling and annotation.
Data analysis
For plasma samples variant calling was performed on
Ion Reporter™ (IR) Analysis Software v5.6 using the
Oncomine™ TagSeq Breast v2 Liquid Biopsy w2.0,
Oncomine™ Lung Liquid Biopsy w1.3, and Oncomine™
TagSeq Pan-Cancer Liquid Biopsy w2.0 workﬂows. The
analysis pipeline also included signal processing, base
calling, quality score assignment, adapter trimming, PCR
duplicate removal, and control of mapping quality. Cov-
erage metrics for each amplicon was obtained by running
the Coverage Analysis Plugin software v5.6.1 (Thermo
Fisher Scientiﬁc). Identiﬁed variants were only considered
if the variant had a molecular coverage of at least three,
indicating that the variant was detected in three inde-
pendent template molecules. Finally, all candidate muta-
tions were manually reviewed using the Integrative
Genomics Viewer37.
For tissue samples, the default analysis pipeline in IR
(Oncomine™ Solid Tumor Assay, Oncomine™ Focus
Assay, Oncomine™ Comprehensive v3) was used.
Results
Plasma volume and cfDNA amount deﬁne LOD for variant
calling
First, we attempted to establish a solid workﬂow for the
extraction of cfDNA from plasma of either healthy indi-
viduals or cancer patients. Table 1 summarizes the ana-
lyzed cohort characteristics. Peripheral whole blood was
collected in commercial vessels containing EDTA or a
preservative agent preventing cell lysis and thus the
contamination of circulating cfDNA with cellular DNA.
After plasma isolation, we extracted cfDNA using a
magnetic beads-based kit as described in detail in the
Materials and methods section. The amount of plasma
available varied between 0.4 and 2.0 ml in healthy indivi-
duals and 1.5 and 5.5 ml in cancer patients (Fig. 1b, c,
Materials and methods). As previously reported (ﬁrst in
1977 (ref. 38)), total cfDNA concentration in plasma was
signiﬁcantly higher in cancer patients compared to heal-
thy subjects (p= 0.0006, Fig. 1a). We characterized the
correlation between plasma input and total cfDNA yield
in samples collected from healthy donors (ρ= 0.244, p=
0.0089, shown in Fig. 1b) and cancer patients (ρ= 0.587,
Fig. 1 Total cfDNA yield of plasma samples deriving from healthy donors or cancer patients. a cfDNA concentration in plasma of healthy
individuals compared to cancer patients (Mann–Whitney p= 0.0006). Median, interquartile range, and minimum/maximum are shown in the boxplot.
b Correlation of plasma volume and the total cfDNA output in healthy donors (n= 114, Spearman ρ= 0.244, p= 0.0089). c Correlation between the
plasma volume and the total cfDNA output in cancer patients (n= 63, Spearman ρ= 0.587, p < 0.0001)
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Fig. 2 (See legend on next page.)
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p < 0.0001, shown in Fig. 1c). Next, we processed cfDNA
samples from healthy and cancer donors for NGS library
preparation and sequencing. NGS library concentration
was signiﬁcantly affected by cfDNA input in both healthy
and cancer samples (ρ= 0.348, p= 0.0088 and ρ= 0.699,
p < 0.0001, respectively, Fig. 2a, b). Notably, as healthy
individuals generally present with lower levels of cfDNA
compared to cancer patients, limited DNA input was used
for library preparation, often below the minimal manu-
facturers’ recommended amount (i.e. 10 ng). We show
that the limit of detection (LOD) of our assay, which
indicates the lowest variant allelic frequency that could be
reliably detected, is clearly affected by the cfDNA abun-
dance in both healthy individuals and cancer patients (Fig.
2c, d) with an inverse correlation between these two
variables. Despite comparable sequencing depth in heal-
thy and cancer donor samples (Fig. 2e), we observed
higher molecular coverage in cancer samples (Fig. 2f, p <
0.0001) due to higher amount of input cfDNA. For the
same reason the LOD was signiﬁcantly lower in cancer
patients (Fig. 2g, p < 0.0001). Thus, our data show that the
amount of cfDNA has a direct impact on sequencing
performance and LOD.
cfDNA proﬁling of cancer patients and concordance with
tissue
Previous studies demonstrated the high analytical sen-
sitivity of using molecular barcodes, also referred to as
unique molecular identiﬁers (UMIs23,24,39) for NGS. Here
we attempted to investigate the concordance, in terms of
corresponding detected variants, between circulating
cfDNA and matched tissue from primary tumor or
metastasis of the same patient. To this end, we analyzed
cfDNA obtained from eight breast cancer patients using
the HeliXgyn protocol (developed by the Bioscience
Institute and based on the Oncomine™ cfDNA Breast v2
Assay) and 30 non-small cell lung cancer (NSCLC)
patients using the HeliXmoker protocol (developed by the
Bioscience Institute and based on the Oncomine™ cfDNA
Lung Assay) and sequentially compared it with the results
obtained by sequencing tissue using a suitable Oncomine™
Assay (detailed about used gene panels in Supplementary
Table 1). We used molecular barcoded sequencing (Tag
Sequencing barcodes) to proﬁle our liquid biopsy samples.
As the target regions of the panels used for cfDNA and
tissue proﬁling were not fully overlapping, we focused
only on clinically relevant mutations covered by both
panels (Supplementary Table 1). Our data highlight (Fig.
3a) a substantial level of concordance (71%) between
cfDNA and tissue mutational proﬁles of matched samples.
This suggests that cfDNA analysis reliably mimics tissue
genomic features. Furthermore, additional clinically rele-
vant mutations were detected by liquid biopsy in 26% of
the samples showing a concordant result (Fig. 3a, “plus
Clinical Beneﬁt”). The most frequently observed muta-
tions occurred within the coding region of PIK3CA (6 out
of 18 mutations detected) for breast cancer (Fig. 3b) and
EGFR (40 out of 57 mutations detected) for NSCLC
specimens (Fig. 3c). All mutations detected are summar-
ized in a concordance matrix (Supplementary Fig. 2A, B
for breast and lung cancer samples, respectively). In breast
cancer samples, we found concordance for mutations
detected in PIK3CA, AKT1, and ERBB3, whereas muta-
tions in TP53, ESR1, and BRAF were more often detected
by plasma alone (Fig. 3b). In lung cancer samples, dele-
tions in the EGFR coding regions were more often
detected only by tissue, whereas for substitution in EGFR
we observed a more prevalent fraction detected only by
plasma (Fig. 3c). The time interval between tissue and
blood collection ranged from 0 to 70 months with inter-
vening treatment, suggesting that tumor evolution and
not only tumor heterogeneity could be the underlying
reason for incongruence between tissue and liquid biopsy
analysis. We analyzed the effect of time occurring
between tissue biopsy and blood collection on con-
cordance (shown in Supplementary Fig. 2C). We observed
a trend of decreased time interval between tissue and
liquid biopsy for concordant samples, however, without
reaching statistical signiﬁcance (p= 0.4325). Among
mutations detected by plasma only, the EGFR T790M
resistance mutation was the most frequent (32% of all
mutations detected by plasma and not by tissue NGS
analysis, Fig. 3d). This mutation was likely not detected in
the initial tissue biopsy because it is known to emerge
during therapy as a resistance mechanism against
tyrosine-kinase inhibitor treatment of EGFR-mutated
tumors. These data conﬁrm the effectiveness of our
testing strategy and highlight the clinical value of using
liquid biopsy as a complementary tool to tissue biopsy for
monitoring tumor evolution during treatment.
(see ﬁgure on previous page)
Fig. 2 Comparison of pre-analytical variables from healthy and cancer donor samples. a, b Correlation of library concentration and input of
cfDNA in healthy individuals (n= 55, Spearman ρ= 0.348, p= 0.0088) and cancer patients (n= 40, Spearman ρ= 0.699, p < 0.0001). c, d Correlation
of LOD and cfDNA input in healthy (n= 55; Spearman ρ=−0.551, p < 0.0001) and cancer donors (n= 40; Spearman ρ=−0.790, p < 0.0001). e
Mapped reads of samples deriving from healthy and cancer donors (Mann–Whitney p= 0.1422). f, g Median molecular coverage (Mann–Whitney p
< 0.0001) and LOD (Mann–Whitney p < 0.0001) in healthy and cancer donors. Median, interquartile range, and minimum/maximum are shown in the
boxplot
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cfDNA proﬁling of healthy individuals
Finally, we attempted to proﬁle the cfDNA of indivi-
duals that were healthy (as above deﬁned) at the time of
blood collection. Our patient cohort comprised n= 106
women that underwent a control screening mammo-
graphy test and had been followed-up regularly for up to
10 years later (Table 1). Mammography screening and
blood collection were performed concurrently. For this
study, we divided the healthy individuals into four groups
based on clinical status at follow-up (Table 1). Individuals
belonging to group I (n= 25) did not develop any breast
cancer or other malignancies during follow-up time. In
group II individuals (n= 52) experienced ﬁbrocystic
breast changes such as ﬁbroadenoma and hyperplasia
during follow-up time, while in group III (n= 15) they
developed breast cancer. Donors allocated to group IV (n
= 14) developed a solid tumor other than breast cancer
(speciﬁcally: laryngeal squamous cell carcinoma, glio-
blastoma multiforme, basal cell carcinoma, and thyroid
cancer). The average follow-up time was 8.5 years and did
not differ signiﬁcantly between the four groups described
(Supplementary Fig. 3, Table 1). As reported in the ﬁrst
section of our results, we successfully achieved cfDNA
extraction from all plasma samples, with values ranging
from 1.7 to 30.8 ng/ml of cfDNA (Fig. 1a). Based on
recovery rate and quality of cfDNA (described in Sup-
plementary Fig. 1 and Material and methods), we selected
55 samples for downstream NGS analysis (group I= 12/
25; group II= 23/52; group III= 11/15; group IV= 9/14;
total= 55/106). We processed the selected samples using
the HeliXgyn workﬂow and we selected six samples for a
broader mutational analysis using the HeliXafe protocol
(based on the Oncomine™ cfDNA Pan-Cancer Assay). The
turnaround time from start of plasma processing to data
analysis was on average six working days for these
55 samples, conﬁrming that we have established a fast
workﬂow (Supplementary Fig. 2D). The results of the
molecular proﬁling are summarized in Fig. 4. No genetic
Fig. 3 Concordance analysis of liquid and tissue biopsy in cancer patients. a Representation of the percentage of overall concordance of
matched tissue and liquid biopsy. “+Clinical beneﬁt” refers to additional clinically relevant mutations that were detected through NGS analysis of
liquid biopsy and not tissue biopsy (see “plasma only” in the next sections). No concordance was observed in 29% of the samples, whereas out of
71% concordant samples 26% carried additional clinically relevant mutations detected by plasma only (+ Clinical Beneﬁt). b, c Number of observed
variants for breast (b) and lung (c) cancer samples. Only clinically relevant variants covered by both tissue and plasma NGS panels were considered
for the analysis. d Distribution of gene alterations detected by NGS analysis of plasma and not detected in tissue (total n= 24). Among the clinically
relevant mutations that were detected through NGS analysis of liquid biopsy and not tissue biopsy, the most frequent (32%) is T790M in EGFR.
Mutations found by plasma alone were subdivided in the “+ Clinical Beneﬁt” category if they were part of additionally clinically relevant mutations
detected by plasma alone in samples showing overlap in tissue and plasma mutational proﬁles (i.e. concordance for oncogenic drivers). The “No
Concordance” category indicates mutations detected in samples showing no overlap in tissue and plasma mutational proﬁles
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alterations were found in the cfDNA of most healthy
individuals (84%) (Fig. 4a). Among the four groups of
healthy individuals with different outcomes at follow-up,
no signiﬁcant difference was observed in terms of pre-
analytical variables, including cfDNA concentration in
plasma or achieved molecular coverage (Fig. 4b, c). In 7 of
the 55 cases analyzed, we detected clinically relevant gene
mutations, speciﬁcally six known germline variants
observed at allelic frequencies above 40% and four known
cancer hotspot mutations (Fig. 4d, e). In conclusion, our
results provide evidence that genetic alterations related to
cancer occurrence can be detected in healthy individuals
by analyzing cfDNA.
Discussion
Liquid biopsy has recently gained substantial attention
in the ﬁeld of cancer diagnostics. Ambitious efforts are
currently placed towards the implementation of liquid
biopsy as an early cancer detection method (i.e. before
cancer-related symptoms occur) and ctDNA mutation
analysis has already been reported in early-stage
tumors26–28,40. Early diagnosis possibly equals to a bet-
ter disease outcome; however, large-scale validation stu-
dies are required to better understand the full potential
and the limitations of this application of liquid biopsy36.
The screening of pre-cancerous lesions in asymptomatic
individuals is hindered by several challenges. Namely, the
Fig. 4 Genetic alterations detected in the cfDNA of healthy individuals. a No genetic alteration was detected in 84% of the assayed samples;
however, we detected six germline and four hotspot variants in seven different samples. b, c Pre-analytical variables as cfDNA concentration in
plasma (b) and median molecular coverage (c) in the four groups of healthy donors (Kruskal–Wallis p= 0.9223 and p= 0.7721, respectively). Group I:
healthy at follow-up time; group II: benign breast condition at follow-up time; group III: breast cancer at follow-up time; group IV: a solid tumor other
than breast cancer at follow-up time. Median, interquartile range, and minimum/maximum are shown in the boxplot. d Mutational matrix indicating
the variants detected in healthy individuals belonging to the four groups. Each line represents a patient. Yellow squares represent hotspot variants;
gray squares represent germline variants. e Table summarizing the hotspot variants detected in healthy individuals. LOD limit of detection, AF allele
frequency; TtD Time to hyperplasia/cancer Detection, [cfDNA] cfDNA concentration in plasma (cfDNA ng/plasma ml)
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number of mutant ctDNA molecules present in plasma is
mostly proportional to tumor burden9, rendering detec-
tion particularly problematic in patients with localized
cancer and asymptomatic individuals. Another challenge
is represented by the lack of knowledge regarding the
molecular basis of tumor initiation. Several studies have
reported the detection of somatic mutations and related
clonal expansion in healthy tissue30–33 associated with age
and tissue proliferative rate41. Some of these mutations
were shown to increase the risk of developing cancer42,43.
The Pre-Cancer Genome Atlas44 will signiﬁcantly
improve our understanding of the role of pre-cancerous
lesions in early stages of tumor formation, improving the
speciﬁcity of early detection screening. At present liquid
biopsy is mainly used in advanced cancer patients; how-
ever, the Circulating Cell-free Genome Atlas (CCGA)
study and the development of early screening methods
such as CancerSEEK27 are opening the way for cfDNA
testing in healthy individuals and early-stage tumor
patients. Our work aimed to contribute to this ﬁeld by
investigating the technical feasibility of using liquid biopsy
for screening healthy individuals. Our cohort comprises
177 individuals, out of which 114 were clinically healthy
and 63 were diagnosed with breast or lung cancer at time
of blood collection. Because of the design of our study,
which included patients undergoing routine mammo-
graphy screening and followed-up for breast cancer
insurgence, all healthy volunteers analyzed were women.
As expected, cfDNA concentration was signiﬁcantly lower
in plasma from healthy individuals compared to cancer
patients (Fig. 1a), with cfDNA concentrations ranging
from 1 to 16.8 ng ml−1 for healthy individuals (with the
exception of one sample which had a concentration of
30.8 ng ml−1 in plasma), consistently with previously
published results34,35. The patient presenting 30.8 ngml−1
in plasma belonged to group II. We did not detect any
mutation for this sample nor found any sign of genomic
contamination. Raised cfDNA concentrations have been
observed in healthy donors under several physiological
conditions (as physical exercise45 or infection46). To
overcome the challenges associated with low input
material as well as enabling the detection of low-
frequency mutations, we have implemented molecular
barcoding13,23,24,39 (reviewed in ref. 47) in our sample
processing workﬂow. We have conﬁrmed the reliability
and accuracy of our method by matched genomic analysis
of tissue and plasma samples in cancer patients (con-
cordance of 71% for our cohort of breast and lung cancer
patients; Fig. 3a). These results are in line with previous
studies reporting sensitivity between 65% and 98%48–51
(reviewed in ref. 7). We did not observe perfect con-
cordance possibly due to tumor heterogeneity and evo-
lution under treatment pressure (Supplementary Fig. 2C).
We then used this method to screen for signs of genomic
instability in healthy donors. We could successfully isolate
cfDNA and produce functional NGS libraries from as
little as 0.9 ml of plasma; however, we recovered material
of adequate quality to undergo NGS library preparation
only for 55 out of 114 patients. Moreover, we observed
higher LOD (Fig. 2g) in healthy donors compared to
cancer patients due to higher cfDNA input in cancer
patients. The availability of lower amounts of plasma for
cfDNA isolation in healthy donors (0.4 and 2.0 ml in
healthy individuals and 1.5 and 5.5 ml in cancer patients)
is a drawback of this study. As healthy individuals present
with lower levels of cfDNA compared to cancer patients
(Fig. 1a), we recommend using higher volumes of plasma
for cfDNA analysis from healthy donors. Importantly, this
would allow for the detection of variants present at low
allelic frequencies, which could be particularly relevant for
discovering the presence of early genomic changes (as
shown by the four cancer hotspot mutations we identiﬁed,
Fig. 4d). Through our analysis, we detected genetic
alterations in 7 out of 55 subjects with evaluable cfDNA
that were considered clinically healthy at the time of
liquid biopsy. Among these mutations, we found six
germline variants and four cancer hotspot mutations. The
observation of germline variants is a byproduct of our
cfDNA analysis. Interestingly, many germline variants
detected in our study are mutations in the coding region
of TP53 that have been consistently reported to correlate
with genomic instability and increased cancer risk52–55.
Those patients might be recommended to have genetic
counseling and upon the decision of a trained certiﬁed
geneticist to access early prevention programs. The four
cancer hotspot mutations detected are recurrent genetic
alterations, clinically classiﬁed as pathogenic or likely
pathogenic. Previous studies have identiﬁed mutations in
saliva and plasma of individuals up to 2 years before
tumor insurgence56,57. We detected cancer hotspot var-
iants in individuals that were diagnosed with a benign
breast condition (group II) or breast cancer (group III) up
to 10 years later and at allelic frequencies ranging from
0.08% to 0.52% (Fig. 4d). Furthermore, the detected hot-
spot mutations have been associated with breast cancer as
well as non-neoplastic proliferation of tissue by several
studies58–69. Observing these mutations in the cfDNA of
healthy donors might be considered as indirect evidence
of genomic instability, as was shown for the PIK3CA p.
H1047R variant62. However, it was also observed that
pathogenic TP53 mutations can be detected in the cfDNA
of healthy controls70 with no correlation to tumor
insurgence. Therefore, the interpretation of these ﬁndings
warrants caution and needs to be carefully considered
before drawing any conclusion. Additional extensive
prospective studies with long follow-up time and available
tissue specimens for individuals who develop cancer will
be required to address the speciﬁcity and sensitivity of
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liquid biopsy as a tool for early cancer detection. In
conclusion, with this work we have established a rapid and
reliable workﬂow that allowed us to interrogate cfDNA
from healthy individuals to study genomic alterations with
a limit of detection as low as 0.08% allelic frequency. The
interrogation of cfDNA from the blood of healthy indi-
viduals could prove to be a prospective tool to detect signs
of genomic instability and to better understand early
events in tumor formation.
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